Nelson Van Denburg & Campbell Wealth Management Group LLC continued to hold its stake in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,218 shares of the company’s stock at the close of the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Eli Lilly and were worth $183,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the last quarter. BlackRock Inc. lifted its position in Eli Lilly and by 2.1% in the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares during the last quarter. State Street Corp lifted its position in Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares during the last quarter. Janus Henderson Group PLC lifted its position in Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the last quarter. 76.61% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.51 during trading hours on Monday, reaching $84.54. 462,930 shares of the company’s stock were exchanged, compared to its average volume of 3,681,078. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market capitalization of $92,520.00, a price-to-earnings ratio of 20.55, a PEG ratio of 1.86 and a beta of 0.34. Eli Lilly and Company has a one year low of $65.66 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.88 earnings per share. equities analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.46%. Eli Lilly and’s dividend payout ratio (DPR) is presently 99.05%.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 772,003 shares of company stock worth $64,837,441 over the last quarter. Insiders own 0.20% of the company’s stock.

A number of research analysts have commented on LLY shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research report on Monday, September 11th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their target price for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $90.25.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Stake Maintained by Nelson Van Denburg & Campbell Wealth Management Group LLC” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-stake-maintained-by-nelson-van-denburg-campbell-wealth-management-group-llc/1729241.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.